$Capricor Therapeutics(CAPR.US)$Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy 4 MINUTES AGO, 8:30 AM EST VIA GLOBENEWSWIRE
Investors' expectations of limited future growth may be causing the low P/S ratio. These conditions form a barrier for the share price unless improved. Consider other vital risk factors before investing in Capricor Therapeutics.
$Capricor Therapeutics(CAPR.US)$Moomoo 24/7· just. Capricor Therapeutics Receives First Milestone Payment Of $10M From Nippon Shinyaku, Co. Under Exclusive Commercialization And Distribution Agreement
Capricor Therapeutics is anticipated to see limited growth in the future, keeping its P/S ratio low. Despite recent growth, its muted future outlook compared to the overall industry could remain a barrier for its share price.
$Capricor Therapeutics(CAPR.US)$Item 7.01 Regulation FD Disclosure. On September 29, 2023, the Company announced a positive outcome from a Type-B clinical meeting with the U.S. Food and Drug Administration (the “FDA”) on the design and execution of HOPE-3, the Phase 3 pivotal trial of CAP-1002 in Duchenne Muscular Dystrophy (“DMD”). Feedback from the FDA on the proposed key clinical and regulatory requirements confirms CAP-1002’s path towards Biologics License Application (“BLA”) submiss...
Trytosaveabit楼主 : Capricor Therapeutics Inc: Granted Subsequent Type-B Clinical Meeting With FDA in Q2 to Continue to Discuss Pathway to Bla